Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Phentolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 7/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 5/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 4/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phentolamine SCHEMBL9751780 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA2AADRA1BADRA2C | |
| Phentolamine SCHEMBL29395338 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA2AADRA1BADRA2C | |
| Phentolamine SCHEMBL293522 | 0.99 | ADRA1A (1.00) | ADRA1AADRA1DADRA2AADRA1BADRA2C | |
| Phentolamine SCHEMBL6431869 | 0.99 | ADRA1A (0.98) | ADRA1AADRA1DADRA2AADRA1BADRA2C | |
| Phentolamine SCHEMBL9057149 | 0.99 | ADRA1A (0.98) | ADRA1AADRA1DADRA2AADRA1BADRA2C | |
| Phentolamine SCHEMBL4343423 | 0.95 | ADRA1A (0.93) | ADRA1AADRA1DADRA2AADRA1BADRA2C | |
| Phentolamine SCHEMBL28535560 | 0.94 | ADRA1A (0.89) | ADRA1AADRA1DADRA2AADRA1BADRA2C | |
| Phentolamine SCHEMBL3938445 | 0.93 | CYP2D6 (1.00) | ADRA1AADRA1DADRA2AADRA1BADRA2C | |
| Phentolamine SCHEMBL40852 | 0.93 | CYP2D6 (1.00) | ADRA1AADRA1DADRA2AADRA1BADRA2C | |
| Phentolamine SCHEMBL3764128 | 0.92 | CYP2D6 (0.98) | ADRA1AADRA1DADRA2AADRA1BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16303 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144798-A1 | Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction | AMGEN INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-3870170-B1 | TREATMENT OF PRESBYOPIA AND MYDRIASIS WITH PHENTOLAMINE | OPUS GENETICS INC (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| US-12529704-B2 | Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2026-01-20 | — | — | US | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| EP-0120165-A2 | A preparation and a process for achieving regional weight control | Greenway III, Frank L. (US) | 1984-10-03 | — | — | EP | claimed |
| US-4443441-A | Fixation of intraocular lenses | GALIN MILES A | 1984-04-17 | — | — | US | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-4310524-A | TCA Composition and method for rapid onset antidepressant therapy | RICHARDSON-MERRELL, INC. (US) | 1982-01-12 | — | — | US | claimed |
| US-4310535-A | PHENTOLAMINE, HALOPERIDOL AND L-5-HYPROXYTRYPTOPHAN | PIERPAOLI WALTER | 1982-01-12 | — | — | US | claimed |
| US-4119102-A | Radio frequency treatment of tumors while inducing hypotension | LEVEEN HARRY H | 1978-10-10 | — | — | US | claimed |
| US-4075335-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | claimed |
| US-3937834-A | ALPHA-RECEPTOR BLOCKER, BETA-RECEPTOR BLOCKER, HIGH BLOOD PRESSURE, ANGINA PECTORIS | CIBA-GEIGY CORPORATION (US) | 1976-02-10 | — | — | US | claimed |